NXL-105

N/A

Report date: 2022/01/24 17:25:03
NME

Base Information

Drug NameNXL-105
Drug Alias NameNXL-105AVE-6971AVE-2221AAVE-6971A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBeta Lactamase inhibitorsDNA topoisomerase inhibitors
TargetsBeta LactamaseDNA topoisomerase
Therapy Area/IndicationsGram-Positive Bacterial InfectionsGram-Negative Bacterial Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAstrazeneca Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsGram-Positive Bacterial InfectionsGram-Negative Bacterial Infections

Other Information

ATC CodeN/A
Related LinksN/A